InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,018.39
(
-0.34%
)
US TECH 100
17,014.00
(
0.91%
)
Dow Jones
37,903.29
(
0.23%
)
Brent Oil
84.15
(
0.72%
)
Bitcoin
57,766.88
(
-0.81%
)
Post# of 251670
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 827
Posts 119535
Boards Moderated 15
Alias Born 09/05/2002

DewDiligence

Member Level

Re: masterlongevity post# 74169

Wednesday, 03/11/2009 12:17:22 PM

Wednesday, March 11, 2009 12:17:22 PM

Post# of 251670
Roche-DNA Deal Hits Snag re Pending Avastin Data

http://online.wsj.com/article/SB123678558882995961.html

›MARCH 11, 2009, 11:52 A.M. ET
By MATTHEW KARNITSCHNIG and DANA CIMILLUCA

Deal talks between Genentech Inc. and Roche Holding AG have hit a snag over dueling interpretations of arcane U.S. Securities and Exchange Commission rules, but the problem is unlikely to derail the transaction, according to people familiar with the matter.

The two drug makers have agreed in principle on the terms of a deal that would value the 44% of Genentech that Roche doesn't already own at $46.7 billion, or $95 per share. But efforts to reach an agreement have been hampered by Roche's outstanding tender offer for Genentech shares, which expires on March 20. The two camps were scrambling Wednesday to resolve the problem.

The issue holding up the deal is how long Roche needs to leave the tender open after reaching an agreement with Genentech's board. A longer period would create a problem for Roche. It wants to sew up the deal before April, when a drug trial on Genentech's new cancer treatment, Avastin, is to be published, say people familiar with the matter. Roche is concerned that Genentech's shareholders would hold out for more money if the results are better than expected.

Speculation spread through the market on Tuesday that there was a dispute between the two camps over amending Genentech's so-called "affiliation agreement" with Roche, but people close to the transaction downplayed those concerns.

In order to reach a deal Genentech must agree to amend the agreement by dropping certain conditions. Those issues have largely been resolved, says a person familiar with the matter, and aren't a major issue in the current negotiations.

Roche, based in Switzerland, needs to receive consent from holders representing 90% of Genentech's outstanding shares to secure full ownership of the company. A Roche spokeswoman had no immediate comment.‹


“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up